Uudempia tutkimuksia samasta aiheesta: https://www.frontiersin.org/journals/nu ... 90674/full
102 potilasta 12 viikon ajan ei viela kovin heppoinen tutkimus.
Tulos lyhyesti: "In summary, this study demonstrates that a ketogenic diet constitutes an effective interventional strategy for patients with metabolic dysfunction-associated fatty liver disease (MASLD): even in the absence of substantial weight loss, it can markedly reduce hepatic fat accumulation and improve insulin sensitivity. "
Tassa artikkelissa https://link.springer.com/article/10.11 ... 25-01494-8 puhutaan myos miten yleistyy maailmalla mutten tieda loytyyko tata uudempaa tietoa "The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis." Lancet Gastroenterol Hepatol. 2022. https://doi.org/10.1016/S2468-1253(22)00165-0.
Insuliiniresistenssi MetS Rasvamaksa
Re: Insuliiniresistenssi MetS Rasvamaksa
Tama on sitten jos on jo diagnosoitu fibroosi, vertaillaan eri ruokavalioiden vaikutusta. https://www.cmjpublishers.com/wp-conten ... brosis.pdf